Haemonetics HAE Plasma — R&D

Other segment segments

Similar metrics at other companies

IRONInternal Research And Development — Research And Development Expense

$11.31M+67.6%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

IMVTReportable Segment — R&D

$29.22M-6.2%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

IRONDISC Zero Nine Seven Four — Research And Development Expense

$8.11M+32.5%

Questions, answered.

What is Haemonetics's plasma — R&D?

Haemonetics (HAE) reported plasma — R&D of $4.94M in Q1 2026.

How has Haemonetics's plasma — R&D changed year-over-year?

Haemonetics's plasma — R&D increased by 15.4% year-over-year, from $4.28M to $4.94M.

What is the long-term trend for Haemonetics's plasma — R&D?

Over 3 years (2023 to 2026), Haemonetics's plasma — R&D has grown at a 11.2% compound annual growth rate (CAGR), from $14.69M to $20.2M.

What does plasma — R&D mean?

Represents the total expenses incurred by the plasma business segment for research and development activities. This includes costs associated with the discovery, design, and clinical testing of new plasma collection technologies and related medical solutions. Monitoring this metric helps investors assess the company's commitment to innovation and long-term product pipeline growth within the plasma market.